Introduction {#Sec1}
============

Biological agents targeting inflammatory cytokines have proven more effective than conventional disease-modifying antirheumatic drugs (DMARDs) for suppressing disease activity and progressive joint damage in rheumatoid arthritis (RA) \[[@CR1]--[@CR11]\]. Patients at high risk of progressive joint damage who are difficult to treat with conventional DMARDs may be a particularly important target population for treatment with biologics. Our recent studies showed that increased urinary levels of C-terminal crosslinked telopeptide of type II collagen (uCTX-II), total pyridinoline/total deoxypyridinoline ratio (uPYD/DPD ratio), joint-space narrowing (JSN) score, and low body mass index (BMI) at baseline were all independent predictive markers for radiographically evident joint damage in patients with RA of \<5 years and treated with conventional DMARDs. Although targeting patients with rapid progression, as assessed by these predictive factors, for treatment with biologics may be beneficial, to date there is no evidence that these agents are equally effective in such high-risk patients. Therefore, this study aimed to investigate the ability of tocilizumab monotherapy to reduce progressive structural joint damage in high-risk patients.

Methods {#Sec2}
=======

Patients with RA of \<5 year duration participating in a prospective 1-year randomized controlled trial of tocilizumab \[Study of Active Controlled Monotherapy Used for Rheumatoid Arthritis, an IL-6 Inhibitor (SAMURAI) trial\] \[[@CR10]\] receiving anti-interleukin (IL)-6-receptor antibody monotherapy (8 mg/kg intravenously every 4 weeks, *n* = 154), were categorized into two or three groups according to their uCTX-II values, uPYD/DPD ratio, BMI, and JSN scores at baseline (cutoff values: 500 ng/mmol creatinine for uCTX-II, median for uPYD/DPD, 0 units for JSN, 18.5 and 25 for BMI). These four factors were shown to be independent predictive markers for radiographically evident joint damage progression in 148 patients with RA treated with conventional DMARDs in the control arm of the SAMURAI trial \[[@CR12]\]. Briefly, this trial established that high baseline uCTX-II, uPYD/DPD ratio and JSN score and a low BMI were independent risk factors for progression of bone erosion as evaluated with the van der Heijde modified Sharp method in patients with RA receiving conventional DMARDs. In addition to these three variables, the JSN score at baseline was also significantly associated with an increased risk of progression of JSN score and total Sharp score (TSS). In this study, we compared the 1-year progression of joint destruction in these high- and low-risk groups in the two cohorts of 148 and 154 patients with RA receiving conventional DMARDs or tocilizumab monotherapy, respectively.

SAMURAI trial {#Sec3}
-------------

In the SAMURAI trial \[[@CR10]\], patients were \>20 years and fulfilled the American College of Rheumatology (ACR; formerly the American Rheumatism Association) 1987 revised criteria for the classification of RA, with a disease duration of ≥6 months and \<5 years. In addition, they had ≥6 tender joints (of 49 evaluated), ≥6 swollen joints (of 46 evaluated), an erythrocyte sedimentation rate (ESR) of ≥30 mm/h, and C-reactive protein (CRP) of ≥20 mg/l. All patients had an inadequate response to at least one DMARD or immunosuppressant. Use of anti-tumor necrosis factor (anti-TNF) agents and leflunomide were not allowed within the 3 months prior to the first dose. Change in dose and type of DMARDs and/or immunosuppressants, plasma exchange therapies, and surgical treatments were not allowed within the previous 4 weeks. Oral corticosteroids (prednisolone up to 10 mg/day) were allowed if the dosage had not been changed during the prior 2 weeks. Patients were randomly assigned to receive either tocilizumab monotherapy at 8 mg/kg intravenously every 4 weeks or conventional DMARD therapy for 52 weeks. For the tocilizumab group, DMARDs and/or immunosuppressants were discontinued from the start of the study. Oral corticosteroids (up to 10 mg prednisolone per day) were allowed, but the dosage could not be increased during the study. Use of one nonsteroidal anti-inflammatory drug (NSAID), including switching to another NSAID, was allowed. For the conventional DMARD group, the dose, type, and combination of DMARDs and/or immunosuppressants, except for anti-TNF agents and leflunomide, could be varied according to disease activity at the discretion of the treating physician. Variations of NSAIDs and/or corticosteroids including intra-articular corticosteroid injections were also allowed.

Assessment of risk of radiographic progression {#Sec4}
----------------------------------------------

Posteroanterior radiographs of the hands and anteroposterior radiographs of the feet were acquired at baseline, week 28, and week 52 (or at the last visit for patients who withdrew from the study prior to week 52). Radiographs were scored using the van der Heijde modified Sharp method \[[@CR13]\] for bone erosion, JSN, and TSS independently by two readers who were well trained and competent to score radiographs in accordance with the method. The readers were blinded to the treatment group and chronologic order of the images. We measured urinary total deoxypyridinoline (uDPD) and total pyridinoline (uPYD) by high-performance liquid chromatography (HPLC) and uCTX-II by enzyme-linked immunosorbent assay (ELISA) (CTX-II CartiLaps^®^ ELISA, NORDIC Biosciences, Herlev, Denmark).

Statistical analysis {#Sec5}
--------------------

All statistical analyses were two-sided, and *p* values \<0.05 were considered significant. All statistical analyses were carried out using SAS (SAS Institute, Cary, NC, USA version 8.2, TS2M0).

Results {#Sec6}
=======

Groups were comparable at baseline for the risk factors previously identified for predicting radiological progression in the DMARDs group (Table [1](#Tab1){ref-type="table"}). As shown in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}, differences in the 1-year changes in radiological erosion and JSN scores between patients in the DMARDs and tocilizumab monotherapy arms varied between subgroups divided according to the baseline levels of each predictive marker for radiographically evident joint damage (uCTX-II, uPYD/DPD, JSN, and BMI). The 1-year changes in radiological erosion scores in patients with high uCTX-II, high uPYD/DPD, or low BMI at baseline, indicating a high risk of progressive joint erosion, were significantly lower in tocilizumab-treated than in DMARD-treated patients (Fig. [1](#Fig1){ref-type="fig"}). Those changes in radiological JSN scores in patients with high uCTX-II, high uPYD/DPD, high JSN, or low BMI at baseline, indicating a high risk of progressive JSN, were also lower in tocilizumab-treated than in DMARD-treated patients (Fig. [2](#Fig2){ref-type="fig"}a--d), and there were proven to be significant differences in cases with high JSN and low BMI (Fig. [2](#Fig2){ref-type="fig"}c, d). In contrast, low-risk patients receiving tocilizumab monotherapy progressed less than patients on DMARDs, although the differences were very small and did not reach statistical significance (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}).Table 1Baseline values in the different patient groupsVariablesCutoff valueDMARDs\
*N* = 145Tocilizumab\
*N* = 157*N*Mean of baseline value ± SD*N*Mean of baseline value ± SDJSN0300320\>011521.1 ± 22.512518.2 ± 21.8uCTX-II (ng/mmol/creatinine)\<50053327.2 ± 104.666337.0 ± 102.9≥500881249.0 ± 1014.9831156.0 ± 585.8uPYD/DPD\<6.8725.8 ± 0.7765.5 ± 0.8≥6.8738.6 ± 1.4818.5 ± 1.3BMI (kg/m^2^)\<18.52017.5 ± 1.22617.5 ± 0.6≥18.5 and \<2510221.5 ± 1.610221.5 ± 1.8≥252127.1 ± 1.72928.2 ± 2.4Criteria were according to criteria of the World Health Organization \[[@CR16]\] employees*JSN* joint space narrowing, *uPYD/DPD* urinary pyridinoline/deoxypyridinoline ratio, *uCTX-II* urinary C-terminal telopeptide of type II collagen, *BMI* body mass index, *SD* standard deviationBMI \<18.5, underweight; ≥18.5 and \<25, normal weight; 25≤, overweight or obeseFig. 1One-year change of erosion scores in tocilizumab-treated rheumatoid arthritis (RA) patients at high risk for developing erosions. One-year change in erosion scores were analyzed for individual risk factors (**a** uCTX, **b** uPYD/DPD, **c** BMI) at baseline. Results are expressed as median (*line* across *boxes*), 25--75% interquartile range (*boxes*), mean (*cross symbol* in *boxes*), standard deviation (SD) (*vertical line* across the *top of the box*), and standard error (*vertical line* across *bottom of the box*). The *filled circles* represent individual values over SD values. Differences in changes in erosion scores were compared by the Wilcoxon rank sum test. *uPYD/DPD* urinary pyridinoline/deoxypyridinoline ratio, *uCTX-II* urinary C-terminal telopeptide of type II collagen, *BMI* body mass index, *TCZ* tocilizumabFig. 2One-year change of joint space narrowing (JSN) scores in tocilizumab-treated rheumatoid arthritis (RA) patients with risk factors for developing JSN. Score changes were analyzed for individual risk factors (**a** uCTX, **b** uPYD/DPD, **c** BMI, **d** JSN) at baseline. Results are expressed as median (*line* across *boxes*), 25--75% interquartile range (*boxes*), mean (*cross symbol* in *boxes*), standard deviation (SD) (*vertical line* across *top of the box*), and standard error (*vertical line* across *bottom of the box*). The *filled circles* represent individual values over SD values. Differences in change in JSN scores were compared by the Wilcoxon rank sum test. *uPYD/DPD* urinary pyridinoline/deoxypyridinoline ratio, *uCTX-II* urinary C-terminal telopeptide of type II collagen, *BMI* body mass index, *TCZ* tocilizumab

Discussion {#Sec7}
==========

Biological agents targeting inflammatory cytokines are more effective at suppressing progression of joint damage than are conventional DMARDs. However, previously reported studies on the efficacies of these agents for slowing radiological damage showed that there was still significant progression in many patients \[[@CR1]--[@CR11]\]. These data allowed us to recognize that many patients on nonbiologic DMARDs show no radiographic progression, and some even show radiographic improvement. Specifically, our previous data showed that 39% of patients treated with conventional DMARDs showed no radiographic progression in 1-year follow-up \[[@CR10]\]. However, biological agents may have side effects. With such knowledge gained from growing experience in the use of biologics, patients would benefit from personalized therapies based on accurate prognostic tools rather than standard therapies that do not evaluate risk factor to guide treatment selection. A better understanding of the prognostic factors for progressive joint damage under nonbiological treatment and appropriate targeting of biologics to patients with RA at high risk of progressive joint damage and disability could enhance risk--benefit balance of RA therapeutic strategies. Thus, many investigators have sought such prognostic factors. Young-Min et al. reported the possible usefulness of matrix metalloproteinase-3 (MMP-3) and uCTX-II in predicting radiographic outcome in RA patients treated with DMARDs \[[@CR14]\], and Charni et al. reported the possible usefulness of urinary type II collagen helical peptide (HELIX-II) \[[@CR15]\]. We found that high baseline levels of uCTX-II, uPYD/DPD, JSN score, and low BMI were independently significantly associated with 1-year progression of joint destruction under conventional DMARDs treatment \[[@CR12]\]. Most of these newly developed or recognized markers are still not widely used in clinical practice; however, further understanding the significance of these markers would facilitate better therapies. Having established these risk factors, the efficacy of biologics for reducing joint destruction in high-risk groups needed to be confirmed to effectively target treatment. Therefore, in this study, subanalysis from a prospective 1-year randomized controlled trial of tocilizumab (SAMURAI trial) was performed to investigate the ability of this agent to reduce progression of structural joint damage in high-risk patients. There was no significant difference in 1-year changes of JSN scores between DMARD- and tocilizumab-treated patients in high-risk groups, as estimated by high uCTX-II, uPYD/DPD. Our data show, however, that tocilizumab monotherapy effectively blocked progression of bone erosion in all high-risk groups as estimated by high uCTX-II, uPYD/DPD, or low BMI and also effectively blocked progression of JSN in high-risk groups as estimated by low BMI or high JSN score, The differences in 1-year changes of erosion and JSN scores between the DMARD- and tocilizumab-treated patients were greatest in the high-risk groups, whereas there was little to no difference in the low-risk group. These findings indicate that the benefit of tocilizumab monotherapy to inhibit bone erosion and JSN progression is maximized in high-risk groups as estimated by high uCTX-II, uPYD/DPD, or low BMI, and by low BMI or high JSN score, respectively. To our knowledge, this is the first comprehensive report showing the usefulness of biomarker targeting strategies for biologics in treating RA. There were smaller and nonsignificant differences in 1-year changes of erosion and JSN scores between patients in the DMARD or tocilizumab monotherapy treatment groups in the low-risk category, although progression was still lower in individuals receiving tocilizumab. The lack of statistical significance can be due in part to the very limited progression in the low-risk group reducing the power to detect differences. These findings also suggest that patients at low risk may benefit less from treatment with biologics unless they develop changes in markers that indicate an increased risk of progression during treatment with conventional DMARDs. On the other hand, the lack of statistically significant differences in 1-year changes of JSN scores between patients in the DMARD or tocilizumab monotherapy treatment groups in the high-risk category might be due to the relatively weak prognostic power of high uCTX-II and uPYD/DPD for JSN progression compared with low BMI or high JSN score \[[@CR12]\].

Establishing means of early discrimination between tocilizumab radiological responders and nonresponders is therefore raised as the next issue to be addressed when considering targeted therapeutic strategies. In conclusion, we demonstrated that tocilizumab monotherapy is effective in reducing radiological progression in patients presenting with risk factors for rapid progression of joint damage.
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